NewAmsterdam Pharma Company N.V. NAMS
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is a cardio-renal-metabolic drug developer. Its lead program, obicetrapib, is in Phase 3 for Hypercholesterolemia / ASCVD. Its next catalyst on record is obicetrapib PREVAIL CVOT: DSMB-conducted interim analysis (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: obicetrapib PREVAIL CVOT — DSMB-conducted interim analysis (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| obicetrapib (monotherapy and FDC with ezetimibe) | LDL-C lowering | small molecule | Phase 3 |
Recent results and decisions
- Sep 29, 2026started First participant dosed in Phase 2b SPINOZA trial (~400 participants, primary endpoint change in plasma p-tau217 at week 52)
today announced the dosing of the first participant in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer's disease.
Filing - Aug 5, 2026positive CHMP (EMA) issued positive opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe; ex-US regulator
Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe
Filing - Mar 31, 2026completed enrollment REMBRANDT Phase 3 completed enrollment of 323 patients in March 2026
In March 2026, the trial completed enrollment of 323 patients.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.